Cargando…

Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer

Romidepsin (FK228), a histone deacetylase inhibitor (HDACi), has anti-tumor effects against several types of solid tumors. Studies have suggested that HDACi could upregulate PD-L1 expression in tumor cells and change the state of anti-tumor immune responses in vivo. However, the influence of enhance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yehui, Fu, Ying, Zhang, Xin, Zhao, Gang, Yao, Yuan, Guo, Yan, Ma, Gang, Bai, Shuai, Li, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838139/ https://www.ncbi.nlm.nih.gov/pubmed/32632663 http://dx.doi.org/10.1007/s00262-020-02653-1

Ejemplares similares

Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
por: Saijo, Ken, et al.
Publicado: (2015)

Romidepsin (FK228) in a Mouse Model of Lipopolysaccharide-Induced Acute Kidney Injury is Associated with Down-Regulation of the CYP2E1 Gene
por: Cheng, Shulin, et al.
Publicado: (2020)

FK228 from Burkholderia thailandensis MSMB43
por: Liu, Xiang-Yang, et al.
Publicado: (2012)

Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome
por: Wang, Tian-yun, et al.
Publicado: (2015)

FK228 Analogues Induce Fetal Hemoglobin in Human Erythroid Progenitors
por: Makala, Levi, et al.
Publicado: (2012)

The structural basis of an NADP(+)-independent dithiol oxidase in FK228 biosynthesis
por: Li, Jie, et al.
Publicado: (2014)

FK228 sensitizes radioresistant small cell lung cancer cells to radiation
por: Li, Hong, et al.
Publicado: (2021)

Mechanistic studies of DepR in regulating FK228 biosynthesis in Chromobacterium violaceum no. 968
por: Qiao, Yongjian, et al.
Publicado: (2018)

Apoptotic Cytotoxic Effects of a Histone Deacetylase Inhibitor, FK228, on Malignant Lymphoid Cells
por: Murata, Makoto, et al.
Publicado: (2000)

Genomics-guided discovery of a new and significantly better source of anticancer natural drug FK228
por: Liu, Xiangyang, et al.
Publicado: (2018)

PD-1 and its ligands are important immune checkpoints in cancer
por: Dong, Yinan, et al.
Publicado: (2016)

Atorvastatin Enhances the Efficacy of Immune Checkpoint Therapy and Suppresses the Cellular and Extracellular Vesicle PD-L1
por: Choe, Eun-Ji, et al.
Publicado: (2022)

A Nicotinamide Phosphoribosyltransferase Inhibitor, FK866, Suppresses the Growth of Anaplastic Meningiomas and Inhibits Immune Checkpoint Expression by Regulating STAT1
por: Deng, Yuxuan, et al.
Publicado: (2022)

The HDAC Inhibitor FK228 Enhances Adenoviral Transgene Expression by a Transduction-Independent Mechanism but Does Not Increase Adenovirus Replication
por: Danielsson, Angelika, et al.
Publicado: (2011)

In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi‐scid/scid Mice
por: Kosugi, Hiroshi, et al.
Publicado: (2001)

Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells
por: Park, Jong Kook, et al.
Publicado: (2018)

Romidepsin-induced neutrophilic urticaria
por: Scott, Brian, et al.
Publicado: (2016)

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
por: Hogg, Simon J., et al.
Publicado: (2017)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017)

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
por: Chatterjee, Samit, et al.
Publicado: (2016)

Romidepsin in the treatment of cutaneous T-cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2011)

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
por: Barbarotta, Lisa, et al.
Publicado: (2015)

Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells
por: Wang, Tian-Yun, et al.
Publicado: (2016)

Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood
por: Keber, Corinna U., et al.
Publicado: (2022)

Ethanol Exposure Up-Regulates PD-L1/PD-1 Immune Checkpoint Pathway and Promotes Mammary Tumor Development
por: Xu, Wenhua, et al.
Publicado: (2022)

HDAC1/2 Inhibitor Romidepsin Suppresses DEN-Induced Hepatocellular Carcinogenesis in Mice
por: Afaloniati, Hara, et al.
Publicado: (2020)

The decay scheme of $^{228}$Fr and $K=0$ bands in $^{228}$Ra
por: Ruchowska, E, et al.
Publicado: (1982)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
por: Kleinman, Adam J., et al.
Publicado: (2020)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

The Role of Immune Checkpoints after Cellular Therapy
por: Schmitz, Friederike, et al.
Publicado: (2020)

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
por: Tang, Tianyu, et al.
Publicado: (2021)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2020)

Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer
por: Lee, Yu Seong, et al.
Publicado: (2020)

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors
por: Nettersheim, Daniel, et al.
Publicado: (2018)

Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma
por: Jiang, Guangyi, et al.
Publicado: (2020)

Diversity of immune checkpoints in cancer immunotherapy
por: Guo, Zhangyan, et al.
Publicado: (2023)

Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice
por: Garcia, Myrna G., et al.
Publicado: (2022)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g0f1prle83jrh6eufraf0fpe9b